The prevalence and management of rifampicin-resistanct tuberculosis at Chris Hani Baragwanath Academic Hospital
| dc.contributor.author | Narsing, Rajiv Manhar | |
| dc.date.accessioned | 2018-08-14T08:37:57Z | |
| dc.date.available | 2018-08-14T08:37:57Z | |
| dc.date.issued | 2017 | |
| dc.description | A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, in partial fulfilment of the requirements for the degree of Master of Medicine in Internal Medicine, Johannesburg, 2017 | en_ZA |
| dc.description.abstract | Background. Early effective management of drug-resistant tuberculosis (TB) is important for the patient, and for infection control. The Xpert MTB/RIF (Cepheid, USA) assay detects Mycobacterium tuberculosis DNA and the presence of rifampicin resistance. Objective. To assess the prevalence and initial management of rifampicin-resistant pulmonary TB (PTB), confirmed by the Xpert MTB/RIF assay, in hospitalised adult patients. Methods. This retrospective descriptive study assessed adult patients from March 2011 to February 2013. Data was obtained from the National Health Laboratory Service database and patient records. Management comprised the submission of additional confirmatory sputum tests, initiation of appropriate anti-TB drug therapy, patient isolation, and proper referral. Results. The prevalence of rifampicin resistance was 10.6% (n=77) of 729 positive assays. The initial management was assessed for the 70 patients with complete records. However of these 70 patients, 12 patients had been discharged and 5 patients had died prior to receiving their results. The management of the total cohort and of the 53 remaining inpatients were analysed separately. The overall confirmatory sputum submission rates were 76%, 60%, 60% and 26% for TB microscopy, Line Probe Assay, TB culture, and drug-susceptibility testing, respectively, and 87%, 72%, 68% and 30%, VI respectively for the 53 remaining patients. Overall, 33% of patients received appropriate anti-TB treatment, 50% were isolated, and 49% were appropriately referred. For the 53 remaining patients, 43% received appropriate drug treatment, 66% were isolated, 64% were appropriately referred, and 19% were not referred. The inpatient mortality rate was 19%. Conclusions. Rifampicin-resistant TB prevalence in-hospital was more than double the national rate. The initial management of patients with rifampicin-resistant PTB was substandard. Submission of paired sputum samples and educating healthcare professionals and healthcare users are of paramount importance to improve the management of drug-resistant TB. | en_ZA |
| dc.description.librarian | XL2018 | en_ZA |
| dc.identifier.uri | https://hdl.handle.net/10539/25311 | |
| dc.language.iso | en | en_ZA |
| dc.subject | Rifampicin | |
| dc.subject.mesh | Tuberculosis | |
| dc.title | The prevalence and management of rifampicin-resistanct tuberculosis at Chris Hani Baragwanath Academic Hospital | en_ZA |
| dc.type | Thesis | en_ZA |